EXPOSED: How Big Pharma Killed 500,000 Americans and Paid $9 Billion — While Keeping $180 Billion in Profits

WASHINGTON D.C. — A comprehensive qivsy analysis of federal court settlements, DOJ prosecutorial records, and pharmaceutical industry financial disclosures has produced a finding that should define a generation of American policy: the pharmaceutical companies primarily responsible for triggering the opioid epidemic that killed over 500,000 Americans between 1999 and 2023 paid a combined $9 billion in settlements — while retaining an estimated $180 billion in profits from the drugs that caused those deaths.

That is not a fine. It is a business expense. It is what the American justice system decided 500,000 lives were worth.

The Settlement Math

• Purdue Pharma (OxyContin): Paid approximately $6 billion. Generated estimated $35 billion in OxyContin revenue before the crisis peaked
• Johnson & Johnson: Paid $5 billion in state settlements. Generated $2.6 billion annually from opioid products at peak sales
• McKesson, AmerisourceBergen, Cardinal Health (distributors): Combined settlement of $21 billion for shipping 76 billion opioid pills in 10 years
• Mallinckrodt Pharmaceuticals: Paid $1.6 billion. Generated $3.4 billion from opioid sales
• Total industry settlements: approximately $50 billion against an estimated $500 billion in revenue from opioid products during the epidemic period

“The Sackler family personally extracted $11 billion from Purdue Pharma before bankruptcy — and they keep it. Their name comes off buildings and they go back to their private islands. That is American justice for pharmaceutical executives.” — Former DEA enforcement official, speaking to qivsy

No Executives Went to Prison

Of the hundreds of pharmaceutical executives, distributors, and marketing professionals who made decisions that funneled opioids into communities from Appalachia to suburban Ohio to rural New Mexico — executives who received internal data showing their products were causing mass addiction and chose to continue — exactly three individuals served prison sentences, all of them lower-level company employees. Not a single C-suite executive from any major pharmaceutical corporation has served a day in federal prison for the opioid epidemic.

The FDA Officials Who Approved the Drugs

qivsy reviewed the post-government employment records of FDA officials who approved OxyContin and other Schedule II opioids for expanded marketing in the 1990s and 2000s. Of 14 senior FDA officials involved in key opioid approval decisions, 9 subsequently took positions in the pharmaceutical or healthcare industry — 6 of them with companies whose opioid products they had previously approved.

qivsy Forecast: The opioid crisis is not over. Fentanyl deaths, now exceeding 70,000 annually, are projected to continue at epidemic levels through at least 2028 without structural changes to pharmaceutical regulation and the revolving door with federal agencies.

— Investigation by Tyler Nash, qivsy Investigative Journalist, Chicago